TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00767468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Sorafenib 400mg BID until disease progression or patient withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Sorafenib 400mg BID until disease progression or patient withdrawal.
Study: NCT00446667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mannitol
Description: 400mg BD for 2 days
Study: NCT00627211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Description: From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
Study: NCT00106145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0752, Notch Inhibitor
Description: Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0752, Notch Inhibitor - 450 mg
Description: Dose 450 mg capsules daily for 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off
Description: Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off
Description: Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg
Description: Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
Study: NCT03291587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personnel Training and Coaching Calls
Description: Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation.
Study: NCT04705831

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruconest
Description: C1 Esterase Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruconest
Description: C1 Esterase Inhibitor
Study: NCT04135274

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil to lymphocyte ratio
Description: Neutrophil to lymphocyte ratio
Study: NCT03453437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion
Description: Mindful self-compassion is a course developed by Kristin Neff and Christopher Germer designed to cultivate self-compassion as measured by three subcategories: self-kindness, mindfulness, and a sense of common humanity. This study will shorten the original 8-week course to 5 sessions, and will include interventions and lectures aimed directly toward addressing evaluative concerns perfectionism.
Study: NCT02041520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega 3 fatty acids
Description: omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
Study: NCT02027220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
Study: NCT02234167

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Risk behaviour and infectious diseases
Description: through counselling, testing vaccination
Study: NCT02027220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
Study: NCT00190411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celiprolol
Description: celiprolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: Untreated controls excluding betablockers
Study: NCT03054402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Escalating doses of BAY1834845 including comparison of solution and tablet in one dose group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study: NCT03849001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Conditions
Description: Light Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Conditions
Description: Moderate Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Conditions
Description: Vigorous Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Conditions
Description: Seated Rest
Study: NCT02143557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-Modified Breast Milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCT formula
Study: NCT01013597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
Study: NCT03948724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education program
Description: Patient will have 5 educational therapy workshops. The first educational therapy workshops will be realized at cycle 1 and the last one within 25 weeks after starting treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Information
Description: Patient receive usual informations
Study: NCT00862628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: 100mg tid, 4 or 8 weeks
Study: NCT01414985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10CUCLN2
Description: There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10\^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10\^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10CUCLN2
Description: There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10\^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10\^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
Study: NCT01531647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg q12h Days 8-21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: 400 mg q12h Days 1-4 and 18-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: 400 mg q12h Days 1-4 and 18-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg q12h Days 8-21
Study: NCT03271203

Intervention type: OTHER
Intervention: Michigan Hand Outcomes Questionnaire
Description: The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.

Intervention type: OTHER
Intervention: Michigan Hand Outcomes Questionnaire
Description: The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.

Intervention type: OTHER
Intervention: Real-time data capture app
Description: Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
Study: NCT02574754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: warfarin 10 mg PO x 1
Study: NCT01783041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose
Description: Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
Study: NCT03722147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
Study: NCT04694404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1,Oxaliplatin
Description: Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-10, q2w)
Study: NCT01871753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Infective Agents
Description: 10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
Study: NCT00753272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2186877A
Description: IM administration, two times one annual dose, 3 different lots will be tested

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix TM
Description: IM administration, two times one annual dose
Study: NCT02583139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Designed Music Narratives
Description: Four music narratives for children each comprising an introductory relaxation exercise, a resource-oriented narrative including guided imagery suggestions and relaxing nature scenarios plus especially composed music.~The narrative and music reflect and support each other.
Study: NCT02463565

Intervention type: OTHER
Intervention: no intervention
Study: NCT00770341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin 4 mg/kg
Description: MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: vancomycin
Description: vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg
Description: MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
Study: NCT03336996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: the motor nerve fiber damaged patient receive a treatment course stem cell transplantation after the hematoma removal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BOLD-fMRI drived DTI scanning
Description: All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BOLD-fMRI drived DTI scanning
Description: All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.
Study: NCT02739360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib 150 mg tablet administered orally twice daily
Study: NCT00234806

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health-e-Access
Description: telemedicine intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-e-Access
Description: telemedicine intervention
Study: NCT04094792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Happify Breather App
Description: Subjects in the intervention group will be cued to breathe at 6 breaths per minute and will receive real time heart rate variability biofeedback. As they increase HRV, screen elements will become more visually appealing.
Study: NCT03769012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Glucan
Description: 95% beta-glucan sourced from whole cell Euglena Gracilis

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose
Study: NCT00960531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001+ QS21 (3mcg)
Description: ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001 (10 mcg) + QS-21
Description: ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001+QS-21 (30mcg)
Description: ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
Study: NCT03416985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral B Healthy Clean Manual Toothbrush
Description: Manual Toothbrush

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BURST Sonic Oral Care
Description: Electric sonic toothbrush

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philipps Sonicare DiamondClean 300 Series
Description: Electric pulsating toothbrush
Study: NCT05518097

Intervention type: OTHER
Intervention: Conventional physical therapy program
Description: Patients with knee osteoarthritis underwent a total of 15 sessions of conventional physical therapy program including hotpack, US, TENS, and exercise 5 days a week, for 3 weeks. Hot pack was applied for 10 minutes, ultrasound was applied continuously at 1 MHz, 1.0 W/cm2 for 10 minutes, and TENS was applied for 30 minutes according to the patient's tolerance. The exercise program consisted of an active, active-assisted range of motion and isometric quadriceps strength training.
Study: NCT04347122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.
Study: NCT02376998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant™ endoluminal procedure
Description: Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:~The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.~After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak.
Study: NCT03609073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina
Description: Suturing system then cutting the bridge between the diverticulum and the esophagus.
Study: NCT00523510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infant feeding counseling that includes Flash-heat
Description: Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infant feeding counseling that includes Flash-heat
Description: Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
Study: NCT02796170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 5mg pill taken once daily
Study: NCT02796170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 5mg pill taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5mg pill taken once daily- placebo of Dapagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5mg pill taken once daily- placebo of Dapagliflozin
Study: NCT04100642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemay808
Description: topical apply

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay808
Description: topical apply
Study: NCT03541551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTT with ologen® Collagen Matrix
Description: ologen® Collagen Matrix approved by Indian health authority with registration numberof MD-1517 will be provided by Aeon Ajanta India Pvt. Ltd. free of cost for this clinical research only.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trab Trab
Description: combined trabeculotomy with trabeculectomy
Study: NCT01682434

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser in situ keratomileusis (LASIK)
Description: Wavefront guided treatment in one eye, conventional in the other.
Study: NCT04100642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay808
Description: topical apply

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay808
Description: topical apply

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical apply

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical apply
Study: NCT04043689

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS (transcranial Alternate Current Stimulation)
Description: This is a single-centric comparative randomized controlled blind and cross-over study.~The order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tACS (transcranial Alternate Current Stimulation)
Description: This is a single-centric comparative randomized controlled blind and cross-over study.~The order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tACS (transcranial Alternate Current Stimulation)
Description: This is a single-centric comparative randomized controlled blind and cross-over study.~The order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control
Study: NCT02913417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres® Yttrium 90
Description: Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: ipilimumab 1mg/kg every 3 weeks x 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
Study: NCT01516242

Intervention type: OTHER
Intervention: No treatment given
Description: Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire